Report Feature
The future of the pharmacogenomics market looks promising with opportunities in cardiovascular diseases, infectious diseases, oncology, neurological diseases, psychiatry, and pain management. The global pharmacogenomic market is expected to grow with a CAGR of 8%-10% from 2020 to 2025. The major drivers for this market are increasing prevalence of several infectious and non-infectious diseases, rising usage in drug discovery processes, increasing demand for personalized drugs, and growing awareness of the benefits associated with pharmacogenomics.
A total of XX figures / charts and XX tables are provided in this more than 150-pages report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global pharmacogenomics market report, please download the report brochure.
In this market, polymerase chain reaction (PCR) is the largest technology of pharmacogenomics, whereas cardiovascular disease is the largest application. Growth in various segments of the pharmacogenomics market are given below:
The study includes trends and forecast for the global pharmacogenomics market by technology, application, end user, and region as follows:
By Technology [Value ($ Million) shipment analysis for 2014 – 2025]:
Sequencing
Polymerase Chain Reaction
Gel Electrophoresis
Mass Spectrometry
Microarray
Others
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
Cardiovascular Diseases
Infectious Diseases
Oncology
Neurological Diseases
Psychiatry
Pain Management
Others
By End User [Value ($ Million) shipment analysis for 2014 – 2025]:
Hospitals & Clinics
Research Institutions and Academic Institutes
Others
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
North America
United States
Canada
Mexico
Europe
United Kingdom
Spain
Germany
France
Asia Pacific
China
India
Japan
The Rest of the World
Brazil
Some of the pharmacogenomics companies profiled in this report include Affymetrix, AstraZeneca, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, Bayer, Merck, GlaxoSmithKline, Johnson & Johnson, Myriad Genetics, and Pathway Genomics Corporation.
Lucintel forecasts that polymerase chain reaction will remain the largest technology segment over the forecast period due to its irreplaceability in terms of use for the amplification of a small segment of DNA.
Within this market, hospitals and clinics will remain the largest end user segment over the forecast period due to better infrastructure and technological edge over other medical centers and the presence of highly skilled medical professionals and patients.
North America will remain the largest region over the forecast period due to increasing usage of pharmacogenomics in the development of more potent as well as personalized medicines and high awareness among physicians and drug developers of the benefits of pharmacogenomics, such as increased reliability and reduced side effects.
|
Features of the Global Pharmacogenomics Market |
|
|
This report answers following key questions |
|
Q.1 What are some of the most promising potential, high-growth opportunities for the global pharmacogenomics market by technology (sequencing, polymerase chain reaction, gel electrophoresis, mass spectrometry, microarray, and others), application (cardiovascular diseases, infectious diseases, oncology, neurological diseases, psychiatry, pain management, and others), and end user (hospitals & clinics, research institutions and academic institutes, and others), and region (North America, Europe, Asia Pacific, and Rest of the World)? Q.2 Which segments will grow at a faster pace and why? Q.3 Which region will grow at a faster pace and why? Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global pharmacogenomics market? Q.5 What are the business risks and threats to the global pharmacogenomics market? Q.6 What are the emerging trends in this pharmacogenomics market and the reasons behind them? Q.7 What are some changing demands of customers in this pharmacogenomics market? Q.8 What are the new developments in this pharmacogenomics market? Which companies are leading these developments? Q.9 Who are the major players in this pharmacogenomics market? What strategic initiatives are being implemented by key players for business growth? Q.10 What are some of the competitive products and processes in this pharmacogenomics market, and how big of a threat do they pose for loss of market share via material or product substitution? Q.11 What M&A activities did take place in the last five years in the global pharmacogenomics market? |
Report Scope
| Key Features | Description |
| Base Year for Estimation | 2019 |
|
Trend Period (Actual Estimates) |
2014-2019 |
| Forecast Period | 2020-2025 |
| Pages | More than 150 |
| Market Representation / Units | Revenue in US $ Million |
| Report Coverage | Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling |
| Market Segments | Technology (Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, and Others), Application (Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Psychiatry, Pain Management, and Others), and End User (Hospitals & Clinics, Research Institutions and Academic Institutes, and Others) |
Regional Scope |
North America (USA, Mexico, and Canada), Europe (United Kingdom, Spain, Germany, and France), Asia (China, India, an Japan), and ROW (Brazil) |
| Customization | 10% Customization without Any Additional Cost |
Table of Contents
1. Executive Summary
7.2 Emerging Trends in the Global Pharmacogenomics Market
4.1 Global Pharmacogenomics Market by Region
4.2.1 Market by Technology: Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, and Others
4.2.2 Market by Application: Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Psychiatry, Pain Management, and Others
4.2.3 Market by End User: Hospitals & Clinics, Research Institutions and Academic Institutes, and Others
4.2.4 The United States Pharmacogenomics Market
4.2.5 The Canadian Pharmacogenomics Market
4.2.6 The Mexican Pharmacogenomics Market
4.3.1 Market by Technology: Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, and Others
4.3.2 Market by Application: Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Psychiatry, Pain Management, and Others
4.3.3 Market by End User: Hospitals & Clinics, Research Institutions and Academic Institutes, and Others
4.3.4 The United Kingdom Pharmacogenomics Market
4.3.5 The Spanish Pharmacogenomics Market
4.3.6 The German Pharmacogenomics Market
4.3.7 The French Pharmacogenomics Market
4.4.1 Market by Technology: Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, and Others
4.4.2 Market by Application: Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Psychiatry, Pain Management, and Others
4.4.3 Market by End User: Hospitals & Clinics, Research Institutions and Academic Institutes, and Others
4.4.4 The Chinese Pharmacogenomics Market
4.4.5 The Indian Pharmacogenomics Market
4.4.6 The Japanese Pharmacogenomics Market
4.5.1 Market by Technology: Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, and Others
4.5.2 Market by Application: Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Psychiatry, Pain Management, and Others
4.5.3 Market by End User: Hospitals & Clinics, Research Institutions and Academic Institutes, and Others
4.5.4 Brazilian Pharmacogenomics Market
7.1.1 Growth Opportunities for the Global Pharmacogenomics Market by Technology
7.1.2 Growth Opportunities for the Global Pharmacogenomics Market by Application
7.1.3 Growth Opportunities for the Global Pharmacogenomics Market by End User
7.1.4 Growth Opportunities for the Global Pharmacogenomics Market by Region
Methodology
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in this market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Buy Now
Choose a license that fits your team. Instant PDF delivery.
Prices exclude taxes. Instant delivery. Custom licensing available on request.
